[go: up one dir, main page]

MX2019000717A - Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos. - Google Patents

Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos.

Info

Publication number
MX2019000717A
MX2019000717A MX2019000717A MX2019000717A MX2019000717A MX 2019000717 A MX2019000717 A MX 2019000717A MX 2019000717 A MX2019000717 A MX 2019000717A MX 2019000717 A MX2019000717 A MX 2019000717A MX 2019000717 A MX2019000717 A MX 2019000717A
Authority
MX
Mexico
Prior art keywords
active ingredients
controlled release
matrix
compositions
polisacarid
Prior art date
Application number
MX2019000717A
Other languages
English (en)
Other versions
MX389461B (es
Inventor
Callegaro Lanfranco
Bianchini Giulio
Morpurgo Margherita
Original Assignee
Jointherapeutics S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jointherapeutics S R L filed Critical Jointherapeutics S R L
Publication of MX2019000717A publication Critical patent/MX2019000717A/es
Publication of MX389461B publication Critical patent/MX389461B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente solicitud describe composiciones que pueden usarse para la liberación controlada de ingredientes activos farmacológicos de una matriz de polisacárido acuoso viscoelástico, y su uso potencial en el tratamiento de diferentes etapas de enfermedades musculoesqueléticas. La combinación de la modulación de liberación de fármaco y la naturaleza viscoelástica de la composición hace posible su uso en el tratamiento de fases agudas y crónicas de enfermedades musculoesqueléticas caracterizadas por un estado inflamatorio, y donde se requieren un efecto terapéutico y una contribución viscosuplementaria.
MX2019000717A 2016-07-19 2017-07-18 Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos MX389461B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102016000075246A IT201600075246A1 (it) 2016-07-19 2016-07-19 Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
PCT/EP2017/068085 WO2018015364A1 (en) 2016-07-19 2017-07-18 Compositions comprising a polysaccharide matrix for the controlled release of active ingredients

Publications (2)

Publication Number Publication Date
MX2019000717A true MX2019000717A (es) 2019-04-22
MX389461B MX389461B (es) 2025-03-20

Family

ID=57610113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000717A MX389461B (es) 2016-07-19 2017-07-18 Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos

Country Status (9)

Country Link
US (1) US20190160183A1 (es)
EP (1) EP3487481B1 (es)
JP (1) JP7157731B2 (es)
CN (1) CN109843267A (es)
CA (1) CA3028042A1 (es)
IT (1) IT201600075246A1 (es)
MX (1) MX389461B (es)
RU (1) RU2748261C2 (es)
WO (1) WO2018015364A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700060530A1 (it) * 2017-06-01 2018-12-01 Jointherapeutics S R L Derivati polisaccaridici idrosolubili, loro procedimento di preparazione e loro usi
JP7703245B2 (ja) * 2021-06-24 2025-07-07 上海雲晟研新生物科技有限公司 ケトロラック液体組成物、その製造方法及び応用
CN115850722B (zh) * 2023-02-22 2023-05-09 翔鹏(北京)生物科技有限公司 一种高效透皮的超分子透明质酸钠制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA949182B (en) * 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ITMI20041245A1 (it) 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
ITPD20060202A1 (it) 2006-05-22 2007-11-23 Univ Degli Studi Trieste Miscele polimeriche di polisaccaridi anionici e cationici e loro impiego
EP2117513A2 (en) 2007-02-05 2009-11-18 Carbylan Biosurgery, Inc. Polymer formulations for delivery of bioactive agents
US8273725B2 (en) 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
EA201300341A1 (ru) 2010-09-16 2013-09-30 Шимода Байотек (Пти) Лтд. Композиция фулвестранта и способы применения
SI2616064T1 (sl) 2010-10-21 2019-12-31 Rtu Pharmaceuticals Llc Pripravki ketorolaka, pripravljeni za uporabo
RU2448120C1 (ru) * 2010-11-01 2012-04-20 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратные комплексы бета-циклодекстрина с 1-{[6-бром-1-метил-5-метокси-2-фенилтиометил-1-н-индол-3-ил]карбонил}-4-бензилпиперазином, обладающие противовирусной активностью, их получение и применение
KR101383941B1 (ko) 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
US20150272877A1 (en) 2012-10-26 2015-10-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
CN103142463B (zh) * 2013-03-05 2015-09-09 宁夏康亚药业有限公司 眼用药物组合物,其制备方法及应用
WO2014153384A1 (en) 2013-03-19 2014-09-25 Flexion Therapeutics, Inc. Corticosteroid formulations for the treatment of joint pain and methods of use thereof
KR101439032B1 (ko) 2013-06-13 2014-09-05 동아에스티 주식회사 피록시캄과 히알루론산을 포함하는 골관절염 치료를 위한 액상 조성물
ITMI20132116A1 (it) 2013-12-18 2015-06-19 Apharm Srl Associazione di glicosamminoglicani e ciclodestrine
CN105030663B (zh) * 2015-07-07 2018-08-31 上海通用药业股份有限公司 一种溶液型醋酸曲安奈德注射液的制备方法
CN104971039B (zh) * 2015-07-07 2018-04-17 上海通用药业股份有限公司 一种含溶液型醋酸曲安奈德的医用产品

Also Published As

Publication number Publication date
US20190160183A1 (en) 2019-05-30
RU2018144958A3 (es) 2020-09-21
IT201600075246A1 (it) 2018-01-19
JP2019524754A (ja) 2019-09-05
EP3487481A1 (en) 2019-05-29
JP7157731B2 (ja) 2022-10-20
WO2018015364A1 (en) 2018-01-25
RU2748261C2 (ru) 2021-05-21
EP3487481B1 (en) 2024-02-21
CA3028042A1 (en) 2018-01-25
RU2018144958A (ru) 2020-08-19
CN109843267A (zh) 2019-06-04
MX389461B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
SV2018005610A (es) Derivados de oxopiridina sustituidos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX2017009482A (es) Formulación farmacéutica.
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
MX2019000717A (es) Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica